CD79B CHIMERIC ANTIGEN RECEPTORS

1 - 72 . (canceled)

73 . A chimeric antigen receptor (CAR) comprising: an extracellular domain that comprises:

a) an anti-CD79B antibody or antigen binding fragment thereof that binds one or more epitopes of a human CD79B polypeptide, wherein the anti-CD79B antibody or antigen binding fragment thereof comprises a variable light chain sequence comprising CDRL1-CDRL3 sequences set forth in SEQ ID NOs: 1-3, 9-11, 17-19, or 25-27 and a variable heavy chain sequence comprising CDRH1-CDRH3 sequences set forth in SEQ ID NOs: 4-6, 12-14, 20-22, or 28-30;

b) a transmembrane domain;

c) one or more intracellular co-stimulatory signaling domains; and

d) a primary signaling domain.

74 . The CAR of claim 73 , wherein the anti-CD79B antibody or antigen binding fragment that binds the human CD79B polypeptide is selected from the group consisting of: a Fab′ fragment, a F(ab′) 2 fragment, a bispecific Fab dimer (Fab2), a trispecific Fab trimer (Fab3), an Fv, an single chain Fv protein (“scFv”), a bis-scFv, (scFv) 2 , a minibody, a diabody, a triabody, a tetrabody, a disulfide stabilized Fv protein (“dsFv”), and a single-domain antibody (sdAb, Nanobody).

75 . The CAR of claim 73 , wherein the anti-CD79B antibody or antigen binding fragment that binds the human CD79B polypeptide is an scFv.

76 . CAR of claim 73 , wherein the anti-CD79B antibody or antigen binding fragment thereof comprises a variable light chain sequence as set forth in any one of SEQ ID NOs: 7, 15, 23, and 31, and/or a variable heavy chain sequence as set forth in any one of SEQ ID NOs: 8, 16, 24, and 32.

77 . The CAR of claim 73 , wherein the transmembrane domain is:

a) isolated from a polypeptide selected from the group consisting of: alpha or beta chain of the T-cell receptor, CDδ, CD3ε, CDγ, CD3ζ, CD4, CD5, CD8α, CD9, CD16, CD22, CD27, CD28, CD33, CD37, CD45, CD64, CD80, CD86, CD134, CD137, CD152, CD154, and PD1;

b) isolated from a polypeptide selected from the group consisting of: CD8α, CD28, CD4, CD45, PD1, and CD152; or

c) isolated from CD8α.

78 . The CAR of claim 73 , wherein the one or more co-stimulatory signaling domains:

a) are isolated from a co-stimulatory molecule selected from the group consisting of: TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, CARD11, CD2, CD7, CD27, CD28, CD30, CD40, CD54 (ICAM), CD83, CD134 (OX40), CD137 (4-1BB), CD278 (ICOS), DAP10, LAT, NKD2C, SLP76, TRIM, and ZAP70;

b) are isolated from a co-stimulatory molecule selected from the group consisting of: CD28, CD134, and CD137; or

c) is isolated from CD137.

79 . The CAR of claim 73 , wherein the primary signaling domain is:

a) isolated from a polypeptide selected from the group consisting of: FcRγ, FcRβ, CD3γ, CD3δ, CD3ε, CD3ζ, CD22, CD79a, CD79b, and CD66d; or

b) isolated from a CD3.

80 . The CAR of claim 73 , further comprising a hinge region polypeptide.

81 . The CAR of claim 80 , wherein the hinge region polypeptide comprises a hinge region of CD8α.

82 . The CAR of claim 73 , further comprising a signal peptide.

83 . The CAR of claim 73 , comprising an amino acid sequence as set forth in any one of SEQ ID NOs: 33-40.

84 . A polynucleotide encoding a CAR of claim 73 or the sequence set forth in any one of SEQ ID NOs: 41-48.

85 . A vector comprising the polynucleotide of claim 84 .

86 . An immune effector cell comprising the vector of claim 85 .

87 . A composition comprising the immune effector cell of claim 86 and a physiologically acceptable excipient.

88 . A method of treating a cancer in a subject in need thereof, comprising administering to the subject a therapeutically effect amount of the composition of claim 87 .

89 . The method of claim 88 , wherein the cancer is a hematological malignancy.

90 . The method of claim 88 , wherein the cancer is non-Hodgkin's lymphoma, acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), hairy cell leukemia (HCL), multiple myeloma (MM), acute myeloid leukemia (AML), or chronic myeloid leukemia (CML).

91 . The method of claim 90 , wherein the non-Hodgkin's lymphoma is Burkitt's lymphoma, small lymphocytic lymphoma (SLL), diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), or marginal zone lymphoma (MZL).

92 . The method of claim 90 , wherein the non-Hodgkin's lymphoma is diffuse large B cell lymphoma (DLBCL).